
News from chinalastnight.com
Top chinalastnight.com News

Cancer · United StatesIncludes license for potential best-in-class PDE3/4 inhibitor (HRS-9821) in clinical development for treatment of COPDAdditional 11 programmes to be developed by Hengrui Pharma and optioned by GSK following phase I completionSee the Story
Hengrui Pharma and GSK Enter Agreements to Develop up to 12 Innovative Medicines Across Respiratory, Immunology & Inflammation and Oncology
58% Center coverage: 44 sources